Seres Therapeutics (MCRB) Interest Expenses (2014 - 2026)

Seres Therapeutics has reported Interest Expenses for 13 years, with the latest figure at $5.0 million in Q1 2026.

• Quarterly Interest Expenses rose 2.13% year-over-year to $5.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $16.3 million (down 26.02% YoY) and the FY2025 annual result came in at $311.0 million, changed 0.39% from the prior year.
• Interest Expenses retreated to $5.0 million in Q1 2026 per MCRB's latest filing, from $123.3 million in the prior quarter.
• Over five years, Interest Expenses peaked at $16.4 billion in Q3 2022 and troughed at $2.1 million in Q1 2022.
• A 5-year average of $1.1 billion and a median of $5.9 million in 2024 frame the typical range for Interest Expenses.
• The sharpest annual moves came in 2022 and 2023: Interest Expenses surged 8033.06% in 2022, then tumbled 99.97% in 2023.
• Over 5 years, Interest Expenses stood at $60.0 million in 2022, then slumped by 83.21% to $10.1 million in 2023, then slumped by 35.79% to $6.5 million in 2024, then soared by 1805.1% to $123.3 million in 2025, then tumbled by 95.96% to $5.0 million in 2026.
• According to Business Quant data, Interest Expenses over the past three periods registered $5.0 million, $123.3 million, and $128.1 million for Q1 2026, Q3 2025, and Q2 2025 respectively.